Aquestive Therapeutics (AQST) Interest & Investment Income (2018 - 2026)
Aquestive Therapeutics' (AQST) quarterly Interest & Investment Income came in at $83000.0 in Q1 2026, down 88.36% year-on-year from $713000.0 in Q1 2025, and down 93.37% quarter-over-quarter from $1.3 million in Q4 2025.
Aquestive Therapeutics (AQST) Interest & Investment Income (2018 - 2026) Analysis & Trends
Aquestive Therapeutics' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $83000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 88.36% year-over-year to $83000.0 in Q1 2026; TTM through Mar 2026 was $3.7 million, a 2.2% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, up 27.06% from the prior year.
- Interest & Investment Income slipped to $83000.0 in Q1 2026 per AQST's latest filing, from $1.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $14.5 million in Q1 2023 and bottomed at -$3000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $329000.0 (2024), against an average of $1.4 million.
- Across the five-year window, Interest & Investment Income jumped 483866.67% in 2023 and sank 97.73% in 2024, its largest moves.
- Year by year, Interest & Investment Income stood at $65000.0 in 2022, then surged by 153.85% to $165000.0 in 2023, then surged by 344.85% to $734000.0 in 2024, then soared by 70.57% to $1.3 million in 2025, then slumped by 93.37% to $83000.0 in 2026.
- Per Business Quant, the three latest AQST Interest & Investment Income figures stand at $83000.0 (Q1 2026), $1.3 million (Q4 2025), and $306000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Aquestive Therapeutics | 456.72 Mn | 456.72 Mn | 13.47 Mn | 83,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,000.00 |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 713,000.00 |
| Dec 31, 2024 | 734,000.00 |
| Sep 30, 2024 | 979,000.00 |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 129,000.00 |
| Mar 31, 2023 | 14.51 Mn |
| Dec 31, 2022 | 65,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 32,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | -33,000.00 |
| Jun 30, 2021 | 373,000.00 |